For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
24
views
0
references
 Top references
cited by
443
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      3,560
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.

          Related collections

          Author and article information

          Contributors
          Juan P. Frías: (View ORCID Profile)
          Journal
          Title: New England Journal of Medicine
          Abbreviated Title: N Engl J Med
          Publisher: Massachusetts Medical Society
          ISSN (Print): 0028-4793
          ISSN (Electronic): 1533-4406
          Publication date (Electronic): June 25 2021
          Affiliations
          [1 ]From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
          Article
          DOI: 10.1056/NEJMoa2107519
          PubMed ID: 34170647
          SO-VID: 23226ddb-2de3-4c8c-9854-03a2aada095c
          Copyright © © 2021
          License:

          http://www.nejmgroup.org/legal/terms-of-use.htm

          History

          Data availability:

          Comments

          Comment on this article

          scite_

          Similar content3,560

          See all similar

          Cited by441

          See all cited by